Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$83.38

-0.16 (-0.19%)

, FIXX

Homology Medicines

$21.75

-0.185 (-0.84%)

20:24
12/17/19
12/17
20:24
12/17/19
20:24

BioMarin not facing competitive PKU threat from Homology Medicines, says Piper

Piper Jaffray analyst Christopher Raymond keeps his Overweight rating and $120 price target on BioMarin (BMRN), saying that any weakness in the stock from from today's Phase 1-2 gene therapy data from competitor Homology Medicines (FIXX) should be bought. The analyst contends that Homology's update is "nothing to write home about" based on the magnitude of the Phe reduction benefit from its HMI-102 gene therapy, maintaining a positive stance ahead of BioMarin's expected IND filing for BMN307 by the end of the year.

BMRN

BioMarin

$83.38

-0.16 (-0.19%)

FIXX

Homology Medicines

$21.75

-0.185 (-0.84%)

  • 17

    Dec

BMRN BioMarin
$83.38

-0.16 (-0.19%)

12/16/19
GSCO
12/16/19
NO CHANGE
GSCO
BioMarin, Regeneron among Goldman's six Healthcare 'laggards' for 2020
Goldman Sachs analysts identified six 2019 "laggards" in Healthcare where it sees the potential for further "re-rates" lower in 2020. The stocks the firm sees underperforming in 2020 are BioMarin (BMRN), Cigna (CI), Centene (CNC), Change Healthcare (CHNG), GlaxoSmithKline (GSK) and Regeneron (REGN). Goldman also recommends watching Anthem (ANTM) for potential downside.
12/16/19
PIPR
12/16/19
NO CHANGE
Target $120
PIPR
Overweight
BioMarin's Phase 3 vosoritide data 'a win,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says he remains "incrementally positive" on Overweight-rated BioMarin after the company reported top-line data from its pivotal Phase 3 trial of vosoritide in children with achondroplasia, saying that while the data were "somewhat sparse," he is encouraged that the placebo adjusted growth velocity was 1.6 cm/year and that this data is "a win." On the safety side, he notes that investors have worried about additional signals of hypotension, and while little in the way of data were provided, he is encouraged to note that there were no clinically significant instances of hypotension. Raymond says he continues to model vosoritide revenue of $129M, $261M and $333M in 2021-2023, respectively, and says the drug represents ~$9/share in his sum of parts. He keeps a $120 price target on the shares.
12/16/19
WBLR
12/16/19
NO CHANGE
WBLR
Outperform
William Blair remains buyer of BioMarin following vosoritide data
William Blair analyst Tim Lugo maintained an Outperform rating on BioMarin Pharmaceutical after the company announced top-line results from the Phase III study of vosoritide, a C-type Natriuretic Peptide (CNP) analogue, for the treatment of achondroplasia met its primary endpoint. Lugo noted that the announcement follows the company's recently released new 54-month vosoritide data from the Phase II I open-label extension study in adolescents with achondroplasia, demonstrating that children in Cohort 3 achieved a statistically significant cumulative mean additional height gain of 9 cm compared with children matched for age and gender in a natural history achondroplasia data set. The analyst said that the company now intends to hold pre-submission meetings in the first half of next year to discuss marketing applications for vosoritide, which he expects will be filed in 2020. Lugo added that he conservatively models a launch in the third quarter of 2021 and anticipates blockbuster potential for vosoritide with peak sales nearing $1B in 2026.
12/17/19
CANT
12/17/19
NO CHANGE
Target $129
CANT
Overweight
BioMarin commercial opportunity for vosoritide underappreciated, says Cantor
Cantor Fitzgerald analyst Eliana Merle continues to see the commercial opportunity for BioMarin's vosoritide as underappreciated. She reiterates an Overweight rating on the shares with a $129 price target after hosting a call with a medical geneticist who manages over 200 achondroplasia patients to discuss the Phase 3 vosoritide topline data. The geneticist viewed the 1.6cm increase in annual growth velocity as highly meaningful given cumulative height gains, Merle tells investors in a research note.
FIXX Homology Medicines
$21.75

-0.185 (-0.84%)

09/24/19
HCWC
09/24/19
NO CHANGE
Target $36
HCWC
Buy
Homology Medicines selloff on manuscript unwarranted, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay says the manuscript published in Molecular Therapy is an attempt at marginalizing Homology Medicines' second platform, its AAVHSC-based, non-nuclease, in vivo gene editing. The manuscript has no bearing on Homology's lead canonical gene therapy program, adds the analyst. The new manuscript, "while making profound claims, falls short in its objectives in many ways," contends Chattopadhyay. The analyst "strongly" disagrees with the observations of the Dudek et al. manuscript and consider the approximately 7% selloff yesterday in shares of Homology Medicines as potentially unwarranted. He remains a buyer on weakness heading into the end of 2019 canonical gene therapy data from HMI-102. Chattopadhyay keeps a Buy rating on Homology Medicines with a $36 price target.
10/31/19
OPCO
10/31/19
INITIATION
OPCO
Perform
Homology Medicines initiated with a Perform at Oppenheimer
Oppenheimer analyst Matthew Biegler initiated coverage of Homology Medicines with a Perform rating.
10/31/19
OPCO
10/31/19
INITIATION
OPCO
Perform
Homology Medicines initiated with a Perform at Oppenheimer
Oppenheimer analyst Matthew Biegler initiated coverage of Homology Medicines with a Perform rating. The analyst is bullish on the long-term prospects of Homology's lead therapy, HMI-102, in the ongoing pheNIX trial, but believes investors "should have tempered expectations heading into initial data from pheNIX, which will likely include few patients and limited follow-up." Biegler said he is Perform-rated until the initial data from the pheNIX trial comes in.
11/01/19
11/01/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Digi International (DGII) initiated with an Outperform at Baird. 2. Wave Life Sciences (WVE) initiated with a Buy at Guggenheim. 3. PPG (PPG) resumed with an Equal Weight at Morgan Stanley. 4. Homology Medicines (FIXX) initiated with a Perform at Oppenheimer. 5. Sarepta (SRPT) initiated with a Buy at Guggenheim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

TLGT

Teligent

$0.40

-0.0025 (-0.62%)

15:53
01/18/20
01/18
15:53
01/18/20
15:53
Conference/Events
Teligent to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AYTU

Aytu BioScience

$0.80

0.0014 (0.18%)

15:48
01/18/20
01/18
15:48
01/18/20
15:48
Conference/Events
Aytu BioScience to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DVA

DaVita

$79.45

0.43 (0.54%)

15:32
01/18/20
01/18
15:32
01/18/20
15:32
Conference/Events
DaVita to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, NFLX

Netflix

$339.56

0.89 (0.26%)

08:47
01/18/20
01/18
08:47
01/18/20
08:47
Periodicals
Peacock's pricing might be 'killer feature,' Barron's says »

This week, Peacock…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

, WMT

Walmart

$114.93

-0.96 (-0.83%)

08:36
01/18/20
01/18
08:36
01/18/20
08:36
Periodicals
Casper IPO highlights tech's promise, troubles, Barron' says »

Mattresses have been…

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

WMT

Walmart

$114.93

-0.96 (-0.83%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 18

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:12
01/18/20
01/18
08:12
01/18/20
08:12
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$324.11

-7.89 (-2.38%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.76

-0.14 (-1.01%)

VWAGY

Volkswagen

$0.00

(0.00%)

FSLR

First Solar

$53.51

-0.42 (-0.78%)

AAPL

Apple

$318.66

3.33 (1.06%)

DQ

Daqo New Energy

$53.61

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/17/20
01/17
16:30
01/17/20
16:30
Options
Preliminary option volume of 28.7M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.